LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Financials Overview

Financials in millions CAD. Fiscal year is May - April.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024
Period Ending	Apr 30, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
Gross Profit Gross Profit Growth	-0.02	-0.02	-	-
Operating Income Operating Income Growth	-3.43	-3.43	-0.42	-0.08
Net Income Net Income Growth	-3.9	-3.9	-0.42	-0.08
Earnings Per Share EPS Growth	-0.17	-0.17	-0.08	-6.33
EPS Growth	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Apr 30, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
Cash & Investments Cash & Investments Growth	0.6	0.6	0.12	0.2
Total Debt Total Debt Growth	-	-	-	0.19
Net Cash (Debt) Net Cash Growth	0.6	0.6	0.12	0
Net Cash Growth	393.49%	393.49%	147336.58%	-
Net Cash Per Share Net Cash Per Share Growth	0.03	0.03	0.02	0.01

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024
Period Ending	Apr 30, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
Operating Cash Flow Operating Cash Flow Growth	-2.04	-2.04	-0.25	0
Free Cash Flow Free Cash Flow Growth	-2.04	-2.04	-0.25	0
Free Cash Flow Growth	-	-	-	-

Valuation

Selected indicators aren't available for this stock.

Data Source: S&P Global Market Intelligence Last updated: Aug 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 17, 2026

Data Sources Report a data error